Provider review
TOM Weight Loss Review: It Says Compounded Drugs Carry Extra Risk — and Names Five Pharmacies
TOM Weight Loss writes, on its own pricing page, that “compounded medications are not FDA-approved and carry additional risks”. Most companies in this category will not say the first half; almost none says the second. It names its physician, dates its price table, names five compounding pharmacies with a dose-by-dose grid — and then quotes the same membership at three different figures within one screen.
Correction, August 2026
This review previously said: “No compounding pharmacy is named, so "licensed pharmacies" cannot be checked against any licensee. […] No state coverage list or exclusions are published.”
That was wrong. Both were absence claims and both were wrong on re-reading. The pharmacies are not in prose — they are column headings over the à la carte price grid, five of them, each with a full dose-by-dose price list underneath. The state answer is published more prominently than almost anything else on the site: it is in the footer of every page, in the legal block, on the homepage, and on a page of its own. We cannot tell you whether the grid's column headings were added after 14 August or whether the original sweep read the prose and not the table, and either answer would be a guess. The checkable lesson is that a pharmacy name in this market is as likely to be a table header as a sentence, and a state answer is as likely to be in a footer as on a coverage page.
It now says: Re-read 2026-08-26. TOM names five compounding pharmacies on its pricing page — Drug Crafters, Luxe Med, Cypress, Empower and Houston Rx — with a 4-week price for every dose from each, qualified as "examples". It serves Texas and Utah only, published in the footer of every page and given its own page at /areas-we-serve, and its eligibility page publishes the clinical criteria in full. Two things stand unchanged: no regulatory category is stated for any of the five, and no certificate of analysis or test result is published for any of them. One new finding replaces the vaguer one this review used to make about membership tiers: the à la carte membership is quoted at $150, $100 and $200 in three different places on the same page.
Writes the most candid sentence about compounded drugs in this batch, names five pharmacies and both its states — then quotes one membership at three different prices on a single screen.
Worth trusting if
- You want a company that states the risks of compounded medication in its own words, in its footer as well as its price page
- You live in Texas or Utah and want the prescribing physician named and licensed, with a registration you can look up
- You want dose-by-dose pricing, per pharmacy, with a date on it
Be skeptical if
- You live outside Texas or Utah — this is a two-state practice and says so
- You want a published certificate of analysis for the lot you would be shipped
- You expect one bill — this is deliberately two, on different cycles, and the à la carte membership is priced three ways
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.tomweightloss.com. A link is not a recommendation to take anything.
Provenance
What TOM Weight Loss actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide — Two ways to buy it, on two different clocks. All-inclusive: $199 a month for Basic, medication included at any dose up to 2.4 mg a week. Or à la carte, where medication is billed by the pharmacy on a FOUR-WEEK supply — thirteen fills a year — from $67 at 0.25 mg to $249 at 7.2 mg depending on which of the five named pharmacies fills it, on top of a membership the page prices at $150, $100 and $200 in three different places. Read 2026-08-26; table dated by TOM as "Updated 2026-06-15".
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 1 products reviewed here. The evidence belongs to the molecule, not to TOM Weight Loss.
1
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from TOM Weight Loss’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded SemaglutideSemaglutide · Compounded (503A)Claim matches the trials
“All medications are prescribed and monitored by a board-certified physician. Prescription required; not all patients qualify. Compounded medications are not FDA-approved and carry additional risks. […] Prices reflect a 4-week supply and are billed by the pharmacy, separately from your $150/month (or $300/quarter) à la carte membership. Exact pricing is confirmed before each fill. Updated 2026-06-15.”
Read on the TOM Weight Loss site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — the trial record for the approved product, which TOM correctly does not claim covers its compounded preparation.
TOM makes no efficacy claim, so nothing here overstates a trial, and re-reading on 26 August did not change that. What it says instead is stronger than silence: "Compounded medications are not FDA-approved and carry additional risks." The second half is the rare part. Sellers who admit the approval gap usually stop at the admission, and saying the products carry added risk works against TOM's own sales. The footer version is stronger still — compounded medications "are not reviewed or approved by the FDA for safety or effectiveness; they are not the same as commercially available brand-name products, and carry additional risks". Its other claims are just as careful: prescription required, not everyone qualifies, exact pricing confirmed before each fill, a date on the price table, and — a fact this review previously reported as absent — the names of the compounding pharmacies whose prices the grid quotes.1
Dispensing chain
Who actually fills your prescription
- Drug Crafters
- Luxe Med
- Cypress
- Empower
- Houston Rx
Read the full account
TOM names five compounding pharmacies, as column headings over a dose-by-dose price grid on its pricing page: Drug Crafters, Luxe Med, Cypress, Empower and Houston Rx. An earlier version of this review said it named none, which was wrong; the correction is at the top of the page. Read the qualifier that comes with them: "Prices below are for a 4-week supply; the pharmacies listed are examples. Pricing and availability may vary and are subject to change." So this is a named set with real prices attached rather than a commitment that yours will be one of the five, and no page says which pharmacy fills which prescription. No regulatory category is stated for any of them — "503A" and "503B" appear on no TOM page — although the footer does describe compounded medications as "prepared by state-licensed pharmacies", which is a description of 503A compounding. The prescriber side is unusually complete: Dr. Tran Le, MD, DABOM, named and licensed with a federal registration published in the footer that a reader can look up, and the operating entity named as Texas Obesity Medicine PLLC.
Read on the TOM Weight Loss site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency result, purity result, sterility standard or named laboratory is published or offered, re-checked 2026-08-26 across the homepage, the pricing page, the eligibility page and the areas-served page. That gap is more conspicuous than it was in August, not less: the site warns you in its own words that compounded medication carries added risk, and it now names five pharmacies you could ask — Drug Crafters, Luxe Med, Cypress, Empower and Houston Rx — without publishing a single result from any of them.
Read on the TOM Weight Loss site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Texas and Utah, and nowhere else. TOM publishes this on every page — "Serving Texas & Utah" in the footer, "Available to patients located in Texas and Utah only" in the legal block, "Licensed in TX & UT" on the homepage — and gives it a page of its own at /areas-we-serve. Its eligibility page adds the clinical criteria in full: a BMI of 30 or higher, or 27 or higher with a weight-related condition, plus being at least 18 and physically located in Texas or Utah.
Read the full licensing claim
HIPAA-secure · Board-certified physician · Licensed pharmacies · Serving Texas & Utah
Read on the TOM Weight Loss site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with TOM Weight Loss
We went through TOM Weight Loss’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Read the whole price structure first. Three membership tiers and two full dose-by-dose medication grids sit on /pricing before any question is asked.
- Check the eligibility page, which publishes the clinical rule rather than making you discover it: a BMI of 30 or higher, or 27 or higher with a weight-related condition, plus being 18 or over and located in Texas or Utah.
- Read the same page's contraindication list — thyroid and endocrine history, pregnancy or nursing, pancreatitis, gallbladder disease, severe gastrointestinal disease, known allergy.
- Confirm the two states on /areas-we-serve, which lists the Texas and Utah cities served and states the practice covers nothing else.
- Press Start Your Consultation. That button leaves tomweightloss.com for a separate host, portal.mytomclinic.com, and the walk could not follow it.
- This walk is PARTIAL and the reason is on our end, not TOM's. Every request to portal.mytomclinic.com from the network this walk ran on failed with a TLS handshake error, and a plain-HTTP request was redirected to a Charter/Spectrum security-filter warning page. That is an ISP block. This review makes no claim that TOM's consultation portal is broken, and nothing beyond the public pages was observed.
- Everything a buyer needs to compare is published before intake. Basic is $199 a month with compounded semaglutide included at any dose up to 2.4 mg a week; Premium is $249 a month with compounded tirzepatide up to 15 mg a week or high-dose semaglutide.
- The à la carte membership is quoted three ways on one page: the card is headed $150/mo with "Billed $100 monthly" directly underneath, the section below calls it "your $100/mo (or $200/qtr) à la carte membership", and the footnote under the price grids says "separately from your $150/month (or $300/quarter) à la carte membership". The homepage says $100/mo.
- Medication on the à la carte route is billed per fill by the pharmacy, for a four-week supply — thirteen fills a year, not twelve. Compounded semaglutide runs from $67 at 0.25 mg to $249 at 7.2 mg; compounded tirzepatide from $118 at 2.5 mg to $549 at 15 mg, depending on the pharmacy.
- The five pharmacies are named as the grid's column headings — Drug Crafters, Luxe Med, Cypress, Empower and Houston Rx — with the qualifier that they are "examples" and that pricing and availability may vary.
- The spread between pharmacies at the same dose is large and visible: 15 mg of tirzepatide is $249 from two of the five and $549 from another.
- The price grid carries its own date — "Updated 2026-06-15" — so a reader can tell how old the figures are.
- Quarterly billing is offered on the memberships at a stated saving of up to 20%.
- A separate Medicare route is advertised at $50 a month for eligible members, in a bar across the top of every page.
- The prescribing physician is named and licensed — Dr. Tran Le, MD, DABOM, with a federal registration published in the footer — and the practice states a deliberate cap of about 500 patients.
TOM Weight Loss support
Assessment
What holds up, and what does not
- It states that "compounded medications are not FDA-approved and carry additional risks". The second half of that sentence is written by almost nobody in this category and works against the seller's own interest.
- The footer says it again and harder: compounded medications "are not reviewed or approved by the FDA for safety or effectiveness; they are not the same as commercially available brand-name products, and carry additional risks".
- It names five compounding pharmacies — Drug Crafters, Luxe Med, Cypress, Empower and Houston Rx — with a full dose-by-dose price from each.
Show 6 more
- It publishes its two states everywhere: footer, legal block, homepage and a page of its own.
- Its eligibility page publishes the clinical rule and the contraindications in full, before anyone starts an intake.
- The prescribing physician is named and licensed with a registration a reader can look up, and the operating entity — Texas Obesity Medicine PLLC — is published.
- It states plainly that "prices reflect a 4-week supply", the disclosure most four-weekly sellers omit.
- The price table carries its own last-updated date, which makes the figures checkable rather than perpetual.
- It says exact pricing is confirmed before each fill.
- The à la carte membership is quoted at three different figures on one page, and a fourth time on the homepage.
- No certificate of analysis or test result is published — conspicuous on a site that warns of additional risk and names five pharmacies you could ask.
- No regulatory category is stated for any of the five: "503A" and "503B" appear on no TOM page.
Show 4 more
- The five pharmacies are qualified as "examples", and no page says which one would fill your prescription.
- The membership and the medication are never added together on the à la carte route, and they run on different cycles: thirteen four-week fills a year against twelve monthly membership charges.
- The same dose can cost more than twice as much depending on the pharmacy — 15 mg of tirzepatide is $118 at the bottom of the 2.5 mg column and $549 at the top of the 15 mg one, and the 15 mg row alone spans $249 to $549.
- Texas and Utah only. That is honestly published and it rules out most of the country.
Verdict
The bottom line
Take TOM at its own word — compounded medication is not FDA-approved and carries additional risks — and then use the opening it gives you, which is bigger than it was a fortnight ago: five pharmacies are named with prices. Ask which of the five would fill yours, and ask that pharmacy for the certificate of analysis covering your lot. TOM publishes none, and its own risk warning is the reason to ask.
Opens www.tomweightloss.com. A link is not a recommendation to take anything.
The sentence
On its pricing page, in its own words:
"All medications are prescribed and monitored by a board-certified physician. Prescription required; not all patients qualify. Compounded medications are not FDA-approved and carry additional risks."
Read that last clause again, because it is rare. And the footer of every page goes further:
"Compounded medications are prepared by state-licensed pharmacies and are not reviewed or approved by the FDA for safety or effectiveness; they are not the same as commercially available brand-name products, and carry additional risks."
Across the companies reviewed this week, the range runs from asserting that compounded drugs are FDA-approved (they are not), through inventing FDA oversight of pharmacies and laboratories, to — at the honest end — acknowledging that compounded products are not FDA-approved.
TOM goes one step further and says they carry additional risks. That is a statement against interest. A company writing it has decided the reader is entitled to know something that makes the sale harder.
Full analysis — 7 more sectionsFive pharmacies, with prices · The membership that costs three things · Four weeks is not a month · Where it operates, and who qualifies · What it still will not tell you · The evidence, and what it covers · What this means if you are buying
Five pharmacies, with prices
This review used to say TOM named none. That was wrong, and the correction is at the top of the page.
The à la carte section of the pricing page carries two grids, and the column headings are pharmacy names:
Compounded semaglutide, 4-week supply
| Dose | Drug Crafters and Houston Rx | Luxe Med | Cypress | Empower | |---|---|---|---|---| | 0.25 mg | $67 | $119 | $99 | $159 | | 1 mg | $149 | $159 | $149 | $189 | | 2.4 mg | $189 | $225 | $225 | $259 | | 7.2 mg | $249 (Houston Rx only) | — | — | — |
Compounded tirzepatide, 4-week supply
| Dose | Drug Crafters and Houston Rx | Luxe Med | Cypress | Empower | |---|---|---|---|---| | 2.5 mg | $118 | $128 | $145 | $249 | | 7.5 mg | $199 | $269 | $299 | $369 | | 15 mg | $249 | $369 | $399 | $549 |
Three things worth noticing.
Two of the five columns are the same column. Drug Crafters and Houston Rx quote the identical figure at every dose they share — all five semaglutide rows and all six tirzepatide rows, to the dollar. Houston Rx then adds three high-dose semaglutide rows nobody else lists. Five names, four price lists.
The spread at a single dose is enormous. 15 mg of tirzepatide is $249 from two of the five and $549 from another — more than double, for the same dose of the same molecule in the same week.
They are examples, not a commitment. The page says so: "the pharmacies listed are examples. Pricing and availability may vary and are subject to change."
So this is a named set with real numbers, not a promise that yours is one of them. It is still far more than almost anyone in this market publishes.
What is not stated for any of the five is a regulatory category. "503A" and "503B" appear on no TOM page.
The membership that costs three things
Here is the one place the pricing page loses its footing. The à la carte membership appears four times, at three figures:
- the plan card is headed $150/mo, with "Billed $100 monthly" directly beneath it;
- the section under it says "Your $100/mo (or $200/qtr) à la carte membership covers your care with Dr. Le";
- the footnote under the price grids says medication is billed "separately from your $150/month (or $300/quarter) à la carte membership";
- and the homepage says "à la carte now $100/mo".
On a site that is otherwise this careful — a dated price table, a stated supply period, a named and licensed prescriber — that is the discrepancy to resolve before the card goes on file.
The two all-inclusive tiers are unambiguous by comparison: $199/month for Basic with compounded semaglutide included at any dose up to 2.4 mg a week, and $249/month for Premium with compounded tirzepatide up to 15 mg a week or high-dose semaglutide. Quarterly billing is offered on both at a stated saving of up to 20%.
Four weeks is not a month
"Prices reflect a 4-week supply."
Four weeks comes round thirteen times a year, not twelve, and most sellers on that cycle simply do not mention it. TOM does — but only on the medication half. The membership bills monthly or quarterly, so an à la carte patient is running two clocks, and the page never adds them together.
Where it operates, and who qualifies
Texas and Utah. That is published in the footer of every page, in the legal block, on the homepage, and on a page of its own at /areas-we-serve.
This review used to say no state list was published. That was wrong too.
The eligibility page then publishes the clinical rule rather than making a prospective patient discover it after paying:
"You likely qualify if you have a BMI of 30 or higher, or BMI of 27 or higher with a weight-related condition such as type 2 diabetes, prediabetes, high blood pressure, high cholesterol, or obstructive sleep apnea."
Plus 18 or over and physically located in one of the two states. The contraindications are listed on the same page — thyroid and endocrine history, pregnancy or nursing, pancreatitis, gallbladder disease, severe gastrointestinal disease, known allergy.
What it still will not tell you
Which of the five pharmacies would fill your prescription.
And no certificate of analysis, potency result or purity result is published for any of them. That gap is larger now, not smaller: the site has told you compounded medication carries additional risk, and it has told you five companies that might make yours. The obvious next document is the one nobody publishes.
The evidence, and what it covers
Semaglutide's phase 3 weight-loss record is substantial. 1 Tirzepatide's is too. 2
TOM does not claim those trials for its product, which is correct: they tested FDA-approved finished drugs made to registered specifications. A compounded preparation is a different article, and TOM's own disclaimer is the clearest statement of that gap in this batch.
What this means if you are buying
This is a company that has told you the truth about the category, in its footer as well as its shop window. Use the opening it gives you.
Ask which pharmacy compounds your prescription — you now have five names to put to them. Ask that pharmacy for the certificate of analysis for your lot. And ask which of the three published à la carte membership figures applies to you, because the page says all three.
Questions
Frequently asked questions
Does TOM Weight Loss say compounded drugs are risky?
Yes, in its own words, twice. Its pricing page reads "Compounded medications are not FDA-approved and carry additional risks", and its site-wide footer goes further: compounded medications "are not reviewed or approved by the FDA for safety or effectiveness; they are not the same as commercially available brand-name products, and carry additional risks." That second clause is written by almost no seller in this category. Most, at best, acknowledge the approval gap; stating that the products carry additional risk is a further step against the company's own commercial interest.
Which pharmacy compounds the medication?
TOM names five, as the column headings over its à la carte price grid: Drug Crafters, Luxe Med, Cypress, Empower and Houston Rx, each with a 4-week price for every dose. An earlier version of this review said it named none; the correction is at the top of the page. Two caveats. The page qualifies the list — "the pharmacies listed are examples. Pricing and availability may vary" — so it is not a commitment that yours is one of the five, and no page says which one would fill your prescription. And no regulatory category is stated for any of them: "503A" and "503B" appear on no TOM page, although the footer describes compounded medications as "prepared by state-licensed pharmacies".
What does TOM Weight Loss cost?
Two structures, and one of them is quoted three ways. All-inclusive: Basic is $199 a month with compounded semaglutide included at any dose up to 2.4 mg a week; Premium is $249 a month with compounded tirzepatide up to 15 mg a week or high-dose semaglutide. Both offer quarterly billing at a stated saving of up to 20%. À la carte: you pay a membership plus the pharmacy directly for medication, and the membership appears as $150/mo on the card, $100/mo in the line beneath it and again in the section below, $200/qtr there, and $300/quarter in the footnote under the grids. Medication on that route runs from $67 to $249 for semaglutide and $118 to $549 for tirzepatide per four-week supply, depending on dose and pharmacy. A separate Medicare route is advertised at $50 a month for eligible members. The grid is dated by TOM as "Updated 2026-06-15".
Is a month of medication really a month?
No. The pricing page states that prices reflect a four-week supply, which comes round thirteen times a year rather than twelve. The membership billed alongside it is monthly or quarterly, so on the à la carte route the two halves of the bill run on different cycles — and the page never adds them together.
Where can I use TOM Weight Loss?
Texas and Utah, and nowhere else. That is published in the footer of every page, in the legal block — "Available to patients located in Texas and Utah only" — on the homepage, and on a page of its own at /areas-we-serve. Its eligibility page also publishes the clinical rule in full: a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, prediabetes, high blood pressure, high cholesterol or obstructive sleep apnea, plus being at least 18 and physically located in one of the two states. An earlier version of this review said no state coverage was published; the correction is at the top of the page.
Compare
Others selling what TOM Weight Loss sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off TOM Weight Loss's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.